Early Time-of-Day Immunotherapy Shows Survival Benefit in Lung Cancer Trial
In a Chinese phase 3 trial (LungTIME-C01) involving 210 patients with advanced non-small cell lung cancer, administering anti-PD-1 immunotherapy before 3:00 PM nearly doubled progression-free survival (11.3 vs. 5.7 months) and significantly improved overall survival (28.0 vs. 16.8 months) compared to later infusions. This early time-of-day treatment was linked to […]